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1. Introduction 
1.1 Kidney disease and cardiovascular mortality 
Cardiovascular disease is a leading case of mortality not only in the whole population but 
also in groups with different, noncardiovascular chronic conditions. Kidney disease is one of 
these and many patients with kidney disease paradoxically do not die from end stage 
kidney failure but from cardiovascular causes. Already mild or moderate renal impairment 
represents a considerable excess risk of cardiovascular mortality. The probability of 
premature death is even more striking in some subgroups of kidney patients – e.g. the 
cardiovascular mortality rate of young end stage renal disease (ESRD) patients is 500 times 
higher as compared with an age-matched control group. The situation is moreover 
complicated by the fact that traditional risk factors (the “Framingham factors”) are of lesser 
predictive value in kidney disease than in general population (Foley et al, 1998,  Magnus 
and Beaglehole, 2001,   Go et al, 2004). 
To explain this dismal picture it is not sufficient to disclose that chronic kidney disease 
(CKD) and chronic renal insufficiency (CRI) is associated with accelerated atherosclerosis 
and abnormal lipid/lipoprotein metabolism (Felström et al., 2003, Lacquaniti, 2010). One 
should keep in mind that “CKD”, “CRI” and “ESRD” are collective terms and the actual 
diseases and conditions behind them are manifold (Table 1). Some of them (e.g. diabetes 
mellitus and hypertension) have a profound effect on lipid metabolism and atherosclerosis 
independently from kidney function already before the manifestation of renal impairment. 
From the data in Table 1 is evident that diabetes and hypertension is behind ESRD in one 
quarter (Great Britain) or even two thirds (USA) of cases.     
The natural history of each underlying disease is dependent on a wide range of factors and 
although the K/DOQI classification based on glomerulal filtration rate is a very useful one 
from practical point of view it does not reveal anything about the pathogenesis of the 
particular condition. 
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Etiology of ESRD 
Great 
Britain 
Australia USA Japan 
Chronic glomerulonephritis 30% 30% 9% 47% 
Diabetic nephropathy 16% 22% 43% 31% 
Hypertension 12% 14% 26% 10% 
Chronic interstitial nephritis 8% 10% 2% 2% 
Polycystic degeneration 6% 6% 2% 2% 
Other/unkown 28% 18% 13% 8% 
Table 1. Etiology of end stage renal disease in different regions of word. (According to 
Viklický, 2006) 
1.2 Accelerated atherosclerosis in CKD 
Despite all above mentioned uncertanities concerning the causal association between renal 
disease and accelerated atherosclerosis there is a considerable amount of knowledge in the 
field of pathophysiology and pathobiochemistry of this topic (Felström et al, 2003, Vaziri, 
2006, Kwan et al, 2007, Saland &t Ginsberg, 2007, Tsimihodimos et al. 2008 and 2011, 
Basnakian at al, 2010; Karumanchi & Thadhani, 2010). An overview of different factors 
influencing the rate of atherosclerosis in CKD, CRI and ESRD is summarized in Table 2. 
These factors however do not act independently but in the frame of a complicated and not 
yet fully understood network (Fig 1.). They are present already in the early phases of kidney 
diseases and in many cases other pathological conditions associated with accelerated 
atherosclerosis (obesity, diabetes, hypertension, etc.) are present, too.  
 
Dyslipidemia (increased triglycerides and LDL-cholesterol, decreased HDL-cholesterol) 
Atherogenic lipid fractions (oxidized and carbamylated LDL, small dense LDL, 
triglyceride rich particles) 
Abnormal values and forms of apolipoproteins (apoB, apoAI, Lp(a)) 
Uremic toxins 
Alterations of calcium and phosphorus metabolism 
Oxidative stress (increased formation of reactive oxygen species and advanced glycation 
endproducts, decreased acitivty of antioxidants) 
Immunodeficiency 
Inflammation 
Malnutrition, hypalbuminemia and proteinuria 
Anaemia 
Physical inactivity 
Ethnicity and genetic polymorphism 
Drug treatment  
Hemodialysis modalities 
Peritoneal dialysis 
Table 2. Factors influencing atherosclerosis development in CKD, CRI and ESRD 
1.3 The aim of this chapter 
In this chapter the authors try to answer some question conserning accelerated 
atherosclerosis and its assessment in CRI patients. In the subsequent parts they: 
www.intechopen.com
 
Lipid and Lipoprotein Abnormalities in Chronic Renal Insufficiency: Review 
 
351 
1. Describe and analyze the lipid and lipoprotein abnormalities in CRI, ESRD and HD. 
2. Show the results of a metaanalysis dealing with methodological problems measuring 
LDL-cholesterol in CRI, ESRD and HD patients and results from a study on analytical 
quality of LDL-cholesterol assessment in real word laboratories. 
3. Give simple advice how to assess cardiovascular risk in CRI, ESRD and HD patients in 
everyday clinical practice. 
Therapeutic attempts and possibilities to normalize the lipid abnormalities and decrease the 
high risk of cardiovascular events in CRI, ESRD and HD patients are not the topics of this 
chapter. 
 
IMPAIRMENT OF KIDNEY 
FUNCTION
UREMIC TOXINSGENETIC
BACKGROUND 
ETHNICITY
OTHER DISEASES, 
PATHOLOGICAL 
CONDITIONS
ABNORMAL LIPID 
STATUS
ALTERED APOPROTEINS
DECREASED 
LIPOPROTEIN 
CATABOLISM
INFLAMMATION
IMMUNE DISORDER
ANAEMIA
PROTEIN LOSS
OXIDATIVE STRESS
GLYCATION
CARBAMYLATION
TREATMENT
DIALYSIS 
MODALITIES
ALTERATIONS IN 
Ca AND  P 
METABOLISM
ENDOTHELIAL DYSFUNCTION
ACCELERATED ATHEROSCLEROSIS
CARDIOVASCULAR MORTALITY
 
Fig. 1. Factors responsible for abnormal lipid metabolism and accelerated atherosclerosis in 
kidney disease form a complicated and intertwined network 
2. Lipid and lipoprotein abnormalities in kidney disease 
2.1 Changes of routinely measured lipid parameters in CRI and HD 
The changes of two basic lipid parameters – the concentration of triglycerides (TG) and total 
cholesterol (TC) in different forms of renal disease are in Table 3. Increased triglyceride 
concentration is a general feature of  kidney disease whereas increased cholesterol is not. 
Assesment the risk of atherosclerosis related morbidity from these two parameters is of course 
not possible because they do not reflect the real metabolic situation sufficiently. Lipids are 
insoluble in blood plasma and therefore they can circulate only in the form of lipoproteins. On 
the other side increased TG alone is an important warning sign of the presence of highly 
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atherogenic triglyceride rich lipoprotein particles (TRL). The concentration of total cholesterol 
on the other side does not provide a valuable information because its carriers can be less and 
more atherogenic or even antiatherogenic. In table 4 data on changes of HDL-cholesterol, non-
HDL-cholesterol and the highly atherogenhic Lp(a) in CRI are shown. LDL-cholesterol is not 
involved in this table for reasons of its analytical uncertainity which is further analyzed in part 
3 of this chapter. From data in Table 3 and 4 the shift towards accelerated atherosclerosis is 
evident – high amount of triglycerides in the lipoproteins and a low level of antiatherogenic 
HDL particles regardless on the form and stage of kidney disease (Vazari, 2006, Saland et 
Ginsberg, 2007, Tsimihodimos et al., 2008, Attman et al., 2010). 
 
Condition Triglycerides Total cholesterol 
Minimal proteinuria Increased No change or decrease 
Heavy proteinuria Increased 
Highly increased in 
nephrotic syndrome 
Chronic renal insufficiency Increased No change 
Hemodialysis Increased 
Controversial data – mostly 
no change 
Peritoneal dialysis Increased Increased 
Table 3. Triglycerides and total cholesterol in different conditions associated with kidney 
disease 
 
Condition Non-HDL cholesterol HDL-cholesterol Lp(a) 
Chronic renal 
insufficiency 
Increased Decreased Increased 
Hemodialysis Increased Decreased Increased 
Peritoneal dialysis Increased Decreased Increased 
Table 4. Non-HDL cholesterol, HDL cholesterol and lipoprotein(a)  in chronic renal 
insufficiency, hemodialysis and peritoneal dialysis  
2.2 Lipoprotein metabolism in health and kidney disease   
Lipoproteins are complex particles consisting from lipids transferred from and to the tissues 
and a phospholipid envelope containing different proteins.  They are not passive containers 
of TG and cholesterol but dynamic particles with variable composition. Both lipoprotein 
turnover and composition is altered in kidney diseases and therefore basic knowledge about 
it is essential for the proper assessment of cardiovascular risk in this special case. 
Lipoprotens are divided int three families: Chylomicrons and their remnants, the VLDL-
IDL-LDL family and the HDL family. Their composition and apoprotein content is in Tables 
5 and 6. 
Chylomicrons produced in enterocytes are carriers of lipids from guts to liver.  There are 
much bigger than the other lipoproteins and during ultracentrifugation they do not 
sediment at all. Chylomicrons contain one molecule of apoprotein is B48 and some 
apoprotein molecules A I, A II and A IV. During their life span they acquire apo E and 
apo C from HDL particles. In contact with muscle and fat tissue capillary endothelial cells 
they release fatty acids through triglyceride lipolysis catalyzed by endothelium-bound 
lipoprotein lipase.  Remnants of chylomicrons are removed by the liver.  
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Lipoprotein Size, nm Density, g/l 
Lipid content, % 
TG CH PL 
Chylomicrons 
Chylomicron 
remnants 
80 – 500 
> 50 
< 0,940 80 – 95 2-7 3-9 
VLDL 
IDL 
LDL 
30 – 80 
25 – 35 
18 – 25 
0,950 – 1,005 
1,000 – 1,019 
1,019 – 1,063 
55 – 80 
20 – 50 
5 – 15 
5 – 15 
20 – 40 
40 – 50 
10 – 20 
15 –25 
20 – 25 
HDL2 
HDL3 
9 – 12 
5 - 9 
1,063 – 1,125 
1,125 – 1,210 
5 – 10 15 – 25 20 – 30 
Table 5. Basic characteristics of lipoproteins (According to Žák, 2002, modified; PL = 
phospholipids) 
 
Apoprotein, function Gene Finding 
A I – activator of LCAT 11q23-qter HDL, CHY 
A II – activator of liver lipase, 
Inhibitor of LCAT 
11q21-q23 HDL, CHY 
A IV – activator of LCAT 11q23-qter HDL, CHY 
B 100 - key protein for assembly and receptor 
binding 
2p23-24 LDL, IDL, VLDL 
B 48 - short form of B 100 The same as B100 CHY 
C I –Cofactor of LCAT 19q12-q13.2 CHY, VLDL 
C II – activator of lipoprotein lipase 19q12-q13.2 CHY, VLDL, HDL 
C III – inhibitor of VLDL transfer into liver 11q23-qter CHY, VLDL, IDL 
D – regulator of cholesterol ester transfer 3q14.2-qter HDL 
E – Transfer of CHY remnants into liver 19q12-q13.2 CHY, VLDL, IDL 
Table 6. Apoprotein function and their occurence in lipoproteins 
After a meal rich in fat the peak value of chylomicrons occurs approximately in 3 hours and 
they disappear in 8 – 9 hours. Visible plasma turbidity is a clear sign of chylomicron 
presence (mostly caused when blood sampling is not realized in fasting state).  
Chylomicrons are not involved singificantly in atherogenesis but in the case of their 
decreased catabolism (which is a case in kidney disease) the accumulated remnants can be 
atherogenic (Chan et al, 2009). 
Endogenous lipid carrier particles are formed in the liver as VLDL. They contain a bigger 
variant of apoB (apoB100) but the function of this protein is the same as in chylomicrons. 
Apoproteins B are of key importance during the assembly of lipoprotein particles and also 
serve as a docking structure when the lipoprotein binds to the LDL-receptor. The interaction 
of VLDL with HDL and with the tissues is similar to that of chylomicrons and during their 
circulation they became smaller – known as IDL and LDL. LDL particles during their 
relatively long life span (t1/2 = 2 – 4 hours and in CRI probably even more) can undergo 
oxidation, glycation and carbamylation. These random postsynthetic events alter the quality 
of liporoteins with a profound effect on their cellular metabolism – e.g. the uptake of 
damaged LDL particles through the scavenger receptor and not through the LDL-receptor. 
Another important topic important for the rate of atherosclerosis (not only) in CRI patients 
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is the presence of small dense LDL particles and (Table 7) and increased levels of abnormal 
particles as Lp(a) – Tables 4 and 8. All these features render the interpretation of basic 
laboratory parameters of lipid/lipoprotein metabolism in regard to the assessment of 
atherosclerosis difficult (Table 9). 
Despite the complicated and sometimes contradictory data on LDL metabolism in CRI, 
ESDR and HD it is possible to summarize the underlying picture in a relatively simple way. 
According to Ikerwaka et al (2005) and  Chan et al (2009) all lipid and lipoprotein alterations 
associated with LDL particles have a common soil – their decreased catabolism.  Increased 
synthesis can play an additonal role in the case of massive proteinuria. 
 
Class Density, g/ml Size, nm % of LDL 
I 1.026 27.5 – 26.0 3 
II 1.028 26.0 – 25.5 16 
III 1.034 25.5 – 24.2 50 
IV 1.048 24.2 – 21.8 22 
V > 1.048 < 21.8 9 
Table 7. Normal density distribution of LDL particles 
 
Lipoprotein Lp(a)  has a similar  structure and composition as LDL particles 
Density:  1,050 – 1,100 
Size:   25 – 35 nm 
Proteins: ApoB 100 and an abnormal protein, Apo(a) attached to the B 100 
                                Apo(a) has a variable molecular weight between 300 – 800 kDa, 
                                its  structure is similar  to the plasminogen (involved in fibrinolysis). 
Subtypes: 6 different forms – F, B and S1 – S4 
Concentration: 0 – 1200 mg/l with abnormal distribution of values. As atherogenic are 
                            considered concentrations above 200 – 300 mg/l 
Lp(a) in CRI: Increased but the cause of increase is not clear. The basic level of Apo(a) 
                                              is probably associated with gene polymorphisms and the kidney 
                            disease is a provocative factor for further increase  (Danesh et al, 2000) 
Table 8. Structure of Lp(a) 
The basic function of HDL is the reverse transport of surplus cholesterol from the tissues to 
liver. HDL particles are synthetized as discoid particles poor in lipids. Nascent HDL (or 
HDL3) particles contain a lot of different apoproteins (70 % of total protein is Apo A-I and 20 
% Apo A-II) crucial in TG and cholesterol metabolism which they exchange with 
chylomicrons and VLDL. Cholesterol bound to the surface of HDL is esterified by the 
enzyme LCAT and the esters are internalized. The cholesterol-ester loaded HDL2 particles 
unload their content through a specific receptor into the liver.  The low number and 
decreased function of LDL particles (manifest as “low HDL-C”) is probably a consequence 
of the enzyme LCAT and the apoprotein A-I. Recently Rosenson et al (2011) highlighted the 
topic of HDL heterogeneity and its possible role in the pathophysiology of accelerated 
atherosclerosis in kidney disease. According to this concept not the low level of “good 
cholesterol” but rather the altered constellation of HDL structure and function is of 
importance in atherogenesis. 
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Tiacylglycerols and cholesterol are insoluble in water. They circulate in the blood 
exclusively as lipoproteins. 
Lipoproteins are complex particles; their cholesterol content (measured or calculated as 
HDL-C and LDL-C) does not reflect their real composition and structure. 
Lipoproteins are dynamic, changing their lipid and protein composition during their life 
span in the circulation. 
Lipoproteins are heterogeneous and their different density is not a simple biological 
variation but it has profound effect on their metabolism. Small dense lipoproteins are 
more atherogenic than those with low density. 
In some people and in some pathological conditions there are also abnormal lipoproteins 
in the blood. One of them is lipoprotein(a)  which is highly aterogenic and its 
concentration is increased in renal disease. 
Some of the assay methods for lipids and lipoproteins are not bulletproof from analytical 
point of view – see part 3 of this chapter 
Table 9. Pitfalls in interpretation of basic lipid parameters from clinical point of view 
3. Methods for measurement and lipids, lipoproteins with special attention to 
LDL-cholesterol measurement  
3.1 Basic lipid assays and the short history of lipid and lipoprotein measurement 
The first cumbersome but at that time reliable colorimetric methods for cholesterol and 
triglyceride assays were developed in the first half of the last century. From  today’s point of 
view obsolete methods were crucial for understanding the association between lipid 
metabolism and cardiovascular disease. Later  there were replaced with enzymatic assays 
and adjusted for the use in automatic analyzers. Isolation of lipoproteins by 
ultracentrifugation giving basis for the today lipoprotein terminology was introduced in the 
40’s of the last century. Analytical and preparative ultracentrifugation is also today the gold 
standard method for quantification, separation and research on lipoproteins. About the 
same time paper electrophoresis (later replaced by agarose and polyacrylamide gel) gave 
the rise not only to an alternative nomenclature  (alpha, pre-beta and beta lipoproteins) but 
also to the epoch-making phenotypic classification of dyslipoproteinemias by Fredrickson & 
Lees in 1965 and a better understanding of the pathobiochemistry of atherosclerosis. This 
methodology is currently reserved only for specialized applications. (For an excellent review 
on this topic see Mcnamara et al., 2006).  
Triglyceride and total cholesterol assays are the starting points of lipid status assessment 
also today but their information value is different. Strictly speaking both are “artefacts” but 
whereas total triglycerides provide an important information about the presence of TRLs, 
total cholesterol itself has a limited diagnostic value.  
3.2 Estimation of LDL-cholesterol 
Lipoproteins are prone to differential precipitation in arteficial conditions (e.g. heparin-
manganese or dextran-magnesium solutions) and this allowed to develop methods to 
separate them without ultracentrifugation or electrophoresis. Based on this procedure in 
70’s first the direct measurement of HDL-C was developed and introduced into clinical 
chemistry. On the other side direct measurement of LDL-C was not possible until the end of 
the century. In the 25 year long interim period there was only one possibility to estimate the 
www.intechopen.com
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
356 
concentration of LDL-C in everyday practice. It was the calculation according to Friedewald 
formula (Friedewald et al, 1972). The formula was based on the analysis of a large LDL 
database created in research laboratories using ultracentrifugation. It was however clear that 
a calculation from three (TC, TG, HDL-C) measured values with their own analytical 
uncertainity is only a recourse from necessity. 
The uncertainity of the currently employed 3rd generation methods is much lower than that 
of the Friedewald formula or the older methods but from strictly analytical point of view 
they are also not sufficient to obtain accurate results (Bairaktari et al., 2005). Another 
unsolved problem is that the assay methods from different providers are not yet 
harmonized at all (Fuentes-Arderiu et al, 2009, Miller et al, 2010). 
3.3 Apoprotein measurements  
The discovery of immunochemical methodology in 70’s made apoprotein assays possible. In 
the same time their function and their role in lipid metabolism was identified. According to 
recent view some of them belong to parameters providing important information when 
assessing cardiovascular disease risk (Ritz & Wanner, 2004, Batista et al, 2005) There are 
three apoproteins which should be measured in each patiens with elevated risk of 
cardiovascular disease: Apoprotein B100, apoprotein A-I and lipoprotein(a). 
Only one molecule of ApoB100 is present in each LDL-type particle (Fig 2). ApoB100 is a big  
molecule (m.w. 550 kDa) crucial already in the synthesis of VLDL and playing an essential 
role in the removal of LDL from the circulation. Measurement of ApoB100 in routine clinical 
practice is possible and in contrast to dynamic and heterogenous entities as “HDL-
cholesterol” and “LDL-cholesterol” is an unambiguously defined analyte. The concentration 
of ApoB100 therefore provides the best information about the presence of LDL-type 
particles circulating in the blood (Olofsson et al, 2007). Elevated concentration apoB100 and 
normal or slightly elevated LDL-C or nonHDL-C is an indirect but valuable marker of small 
dense LDL particles  
Apoprotein A-I is a small molecule (28 kDa) and HDL particles contain several of them. 
They are activators of LCAT, that means the concentration of Apo A-I is a marker of HDL 
particle function and the metabolic activity of the particles and not their size or number.  
 
 
Fig. 2. Apoprotein B100 is a big ringlike flexible molecule holding the whole particle 
together in its different stages of metabolism and making its binding to LDL-receptor 
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4. Analytical accuracy of LDL-C in kidney disease and hemodialysis  
4.1 Metaanalysis of results achieved with Friedewald equation compared to reference 
ultracentrifugation method 
Our metaanalysis contains data from all available published papers dealing (entirely or as 
a part of broader study) with analytical accuracy of LDL-C assessment according to the 
Friedewald equation as compared with the reference UC method in CRI patients. The 
methodology of the metanalysis is described in our previous paper (Gaško et Sánchez-Meca, 
2009). It includes studies from 1990 until the end of year 2010. Four studies were found but 
two of them were further divided according to the details of the study. The basic data of the 
studies are summarized in Table 10 and the results of metaanalysis in Fig 3.  
 
Study, Year Probands Location % Weight Inclusion criteria 
Nauck & al 1, 1996 887 Germany 0.0% healthy (not included) 
Nauck & al 2, 1996 136 Germany 23.2% HD, TG < 4.56 mmol/l 
Nauck & al 3, 1996 171 Germany 29.2% CAPD, TG < 4.56 mmol/l 
Pedro-Botet & al, 1996 101 Spain 17.2% HD, age 20 - 80 years 
Bairaktari & al 1, 2001 54 Greece 9.2% HDs, TG < 2.26 mmol/l 
Bairaktari & al 2, 2001 38 Greece 6.5% HD, TG 2,26 – 4.52 mmol/l 
Bairaktari & al, 2004 86 Greece 14.7% HDs TG < 4.5 mmol/l 
 586  100.0%  
Table 10. Studies included in metaanalysis, divided into subgroups according to inclusion 
criteria. 
Model Study name Statistics for each study Difference in means and 95% CI
Difference Lower Upper 
in means limit limit
Nauck et al 2, 1996                               0,020 -0,045 0,085
Nauck et al 3, 1996                               -0,070 -0,117 -0,023
Pedro-Botet et al 1, 1996                         -0,310 -0,398 -0,222
Bairaktari et al 1, 2001                          -0,110 -0,164 -0,056
Bairaktari et al 2, 2001                          -0,390 -0,521 -0,259
Bairaktari et al, 2004                            -0,180 -0,250 -0,110
Fixed -0,115 -0,142 -0,089
Random -0,163 -0,259 -0,068
-1,00 -0,50 0,00 0,50 1,00
Favours FF Favours BQ
 
Fig. 3. Difference in means LDL-C with 95% CI in 4 studies included with 6 subgroups of 
patients with severe nephropathy on different forms of dialysis, with fixed and random 
effects model summary difference. Forest plot. Units: mmol/l. Patients included 586. 
For patients in different dialysis regimes the summary differences of means of LDL-C is 
0.234 mmol/l, what presents a bias of -4.9%. The information value of this result is much 
higher when compared with results on healthy probands od with results of patients with 
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other diseases. We identified 23 publications including 17 213 patients analyzing accuracy of 
LDL-C assessment on healthy probands or in patients with hyperlipidemia from 1990 until 
2009. The summary differences of means in this setting is 0.108 mmol/l and the bias is 
+2.3%. Furhter 3 papers followed analytical accuracy LDL-C in 350 patients with I and II 
diabetes mellitus or with hepatopathy. Total difference in means in this group was 0.234 
mmol/l,  (bias +6.8%;  Fig 4). 
From these findings it is possible to conclude that calculated concentrations of LDL-C 
according to the Friedewald equation can differ from the true values by almost 12 % 
systemic error. For clinical practice this analytical error can have a unwelcome situation 
because in approximately 7% of patients proper and necessary treatment according to 
guidelines is not prescribed and in another 5 % superfluous treatment is prescribed. This 
second group however is not in a danger of non-treated dyslipidemia because but there is 
problem of pharmacoeconomy.  
Model Study name Statistics for each study Difference in means and 95% CI
Difference Lower Upper 
in means limit limit
Matas et al 2, 1994                               0,370 0,214 0,526
Matas et al 3, 1994                               0,310 0,215 0,405
Hirany et al 1, 1997                              0,180 0,099 0,261
Hirany et al 2, 1997                              0,280 0,234 0,326
Wägner et al, 2000                                0,240 0,197 0,283
Wägner et al, 2003                                0,090 0,038 0,142
Fixed 0,220 0,196 0,245
Random 0,234 0,160 0,309
-1,00 -0,50 0,00 0,50 1,00
Favours FF Favours BQ
 
Fig. 4. Difference in means LDL-C with 95% CI in 3 studies included with 6 subgroups of 
patients with diabetes mellitus or hepatopathy, with fixed and random effects model 
summary difference. Forest plot. Units: mmol/l. Patients included 350. Figure from Gaško & 
Sánchez-Meca, 2009, with permision. 
4.2 Unreliability of LDL-C assessment in everyday laboratory practice 
There is only one method providing a true picture about the composition of the particles 
ultracentrifugation with subsequent chemical analysis of their composition. This method is 
the golden standard and the anchor of all methods used in routine clinical practice.   
For a couple of years there was only one indirect way to estimate the cholesterol content of 
LDL particles. Despite modern methods estimating total cholesterol, HDL-cholesterol and 
triglycerides with a high level of precision and accuracy they have a certain degree of 
uncertainity and the overall uncertainity is too high to give a reliable picture on LDL-
cholesterol even in probands without any confounding factors. In CRI patients the situation 
is even worse. 
Recently clinical chemistry laboratories can use one commercial kits based on 7 different 
method for direct LDL-C assays. Some laboratories however calculate LDL-C according to 
the Friedewald formula or use both procedures (e.g. direct assay only in the case of elevated 
total cholesterol or in patients with otherwise elevated cardiovascular risk). According to 
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Agrawal et al (2010) in USA in 2009 approximately 2200 laboratories used direct assays but 
3300 calculated LDL-C according to Friedewald. In Czech and Slovak republics the ratio was 
different (159 laboratories on direct assays and only 83 on formula (Gaško et al, 2011).  
There is no official recommendation on international level about the methodology of LDL-C 
estimation. The choice depends solely on the decision of the laboratory and/or the health 
care provider. Another confounding factor is that the same laboratory can change the actual 
type of the direct method or use alternatively a direct method or the calculation mostly 
without any warning towards the clinician.   
We realized a multicentric prospective study to compare the results achieved by different 
direct method compared with the results of Friedewald calculation (Gaško et al, 2011) in 13 
laboratories. All of them were controlled also in the frame of an external quality assesment 
system. All of them diclosed results of the control sera in the appropriate range. Results of 
the direct assay and the calculation were compared on a set of randomly selected 200 patient 
samples with a broad range of diseases including CRI. In Fig 5. the average difference 
between the results of direct (considred in this study as reference) method and the 
calculated results are shown. The differences are in the range from -8 % ap to + 30 %.  Of 
course the evident limitation of this study is the lack of comparison with the reference 
ultacentrifugation method. Despite this limitation the results of this simple study combined 
with the results of metanalysis (4.1.) show an unacceptable degree of uncertainity  of LDL-C 
estimation in individual patients not to mention those who are at special risk.  
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Fig. 5. Average differences (n = 200) in calculated LDL-C compared with results of the direct 
assay in 13 different laboratories. Value measured by the direct method in each laboratory is 
considered 100%. Data are shown as median and 2.5 to 97.5 percentiles. 
A very interesting question is the situation after kidney transplatation. These patients at the 
first sight are „cured“ but as a matter of fact they are far from being „healthy“ beacause of 
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the long-life immunosuppression therapy and of the slightly decreased kidney function in 
most of them. Balal et al (2010) compared results from 103 renal transplant recipients and 
the sum of differences between the calculation according to Friedewaldovho and the direct 
method was – 6,5 % ± 6,6 % (mean ± SD). According to Tsimihodimos et al (2008) after 
transplantation one very important atherogenic factor disappears – the increased level of 
Lp(a).  
5. Conclusions 
5.1 Where we stand today? 
From our metaanalysis and the study on the unreliability of LDL-C estimation we conclude 
that the Friedewald formula seems to be no longer a viable test for appropriate targeted 
therapy in chronic renal failure and hemodialysis. Direct assays of LDL-C are not absolutely 
without error but they provide considerably more reliable results as a calculation from three 
measurements. 
Clinicians should be aware that despite our gradually better understanding of the 
pathobiochemistry, pathobiochemistry and genetic background of atherosclerosis and 
kidney disease laboratories are not able to provide full explanation about the situation in 
individual patients. According to McNamara et al (2006) “we are still only scratching the 
surface, and mich more research and discovery remains to fully understand these critically 
important particles”. As is depicted in Fig. 6   the scientist are looking on the different visible 
parts of the problem. The situation in clinical chemistry is even more problematic because 
the currently available methods are showing only the footprints of the real situation, not its 
essence.   
 
Fig. 6. Scientist looking at miscellaneous aspects of the problem and a clinical chemist trying 
to gain some information from the footseps. 
5.2 Conclusion 
In patients with CRI and/or ESRD, HD the pace of atherosclerosis development should be 
estimated as follows: 
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Proper clinical and biochemical evaluation of the underlying kidney disease and continuous 
monitoring of its progression. Special attenttion should be devoted to proteinuria and 
hypalbuminemia because they directly influence the metabolism of LDL-type particles and 
their concentration in the blood. 
Evaluation of the risk factors not directly associated with the kidney disease (smoking, 
obesity, diabetes, hypertension, etc.) 
Evaluation of lipid parameters – total cholesterol, LDL-cholesterol measured directly, HDL-
cholesterol, triglycerides, apoprotein B100, apoporotein AI and Lp(a). The evaluation should 
not be a mechanistical process but should be based on pathophysiology of atherosclerosis in 
renal disease and should consider the strengths and weaknesses of the employed methods.  
Measurement of other parameters not fully validated yet from analytical point of view and 
from their clinical usefulness (small dense LDLs, parameters of the oxidative stress and 
antioxidant systems) is possible for research purposes. 
6. List of abbreviations 
C   Cholesterol (as LDL-C, HDL-C, nonHDL-C) 
CHY   Chylomicron 
CKD   Chronic kidney disease 
CRI   Chronic renal insufficiency 
ESRD   End stage renal disease 
HD   Hemodialysis 
HDL   High-density lipoprotein 
IDL   Intermediate-density lipoprotein 
LCAT   Lecithin-cholesterol acyltransferase 
LDL   Low-density lipoprotein 
TC   Total cholesterol 
TG   Triglyceride 
TRL   Triglyceride rich particle 
VLDL   Very low-density lipoprotein 
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